share_log

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

Atea Pharmicals将于2024年5月14日举办2024年第一季度财务业绩电话会议
GlobeNewswire ·  05/07 07:00

BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update.

马萨诸塞州波士顿,2024年5月7日(GLOBE NEWSWIRE)——从事严重病毒性疾病口服抗病毒疗法发现和开发的临床阶段生物制药公司Atea Pharmicals, Inc.(纳斯达克股票代码:AVIR)(“Atea”)今天宣布,它将在美国东部时间2024年5月14日星期二下午 4:30 举办电话会议和网络音频直播,报告财务状况截至2024年3月31日的第一季度业绩,并提供业务最新情况。

To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on Atea's website approximately two hours after the conference call and will remain available for at least 90 days following the event.

要访问实时电话会议,参与者可以在此处注册。电话会议的网络直播将在Atea Pharmicals网站ir.ateapharma.com投资者关系栏目的 “活动和演讲” 下播出。要通过电话参加,请在此处提前注册。注册后,所有电话参与者都将收到一封确认电子邮件,详细说明如何加入电话会议,包括拨入号码以及可用于接听电话的唯一密码和注册人ID。虽然不是必需的,但建议参与者在预定开始时间前十分钟加入通话。电话会议结束大约两小时后,网络音频直播的档案将在Atea的网站上公布,并且将在活动结束后的至少90天内保持可用。

About Atea Pharmaceuticals

关于 Aeta制药

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging the Company's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the development of orally-available antiviral agents for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV). For more information, please visit .

Atea是一家临床阶段的生物制药公司,专注于发现、开发和商业化口服抗病毒疗法,以满足严重病毒感染患者未得到满足的医疗需求。利用公司对抗病毒药物开发、核酸(t)化学、生物学、生物化学和病毒学的深刻理解,Atea建立了专有的nucleos(t)ide前药平台,用于开发新的候选产品,用于治疗单链核糖核酸或ssRNA病毒,这种病毒是严重病毒性疾病的普遍病因。Atea计划通过使用其他类别的抗病毒药物来增强其核苷酸平台,继续建立其候选抗病毒产品管道,这些抗病毒药物可与其核苷酸候选产品组合使用。目前,Atea专注于开发可口服的抗病毒药物,用于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)、导致 COVID-19 的病毒和丙型肝炎病毒(HCV)。欲了解更多信息,请访问。

Forward-Looking Statements

前瞻性陈述

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the date and time of the Atea's conference call and audio webcast. When used herein, words including "will," "plans", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea's current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed under the caption "Risk Factors" in the reports Atea files with the SEC including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K , as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Atea's views as of any date subsequent to the date of this press release.

本新闻稿包括1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。本新闻稿中的前瞻性陈述包括但不限于Atea的电话会议和网络音频直播的日期和时间。此处使用包括 “意愿”、“计划” 和类似表述在内的词语旨在识别前瞻性陈述。此外,任何涉及预期、信念、计划、预测、目标、业绩或其他未来事件或情况特征的陈述或信息,包括任何基本假设,均为前瞻性。所有前瞻性陈述均基于Atea当前的预期和各种假设。Atea认为其期望和信念有合理的依据,但它们本质上是不确定的。Atea可能没有意识到自己的期望,其信念可能不正确。由于各种重要因素,包括但不限于Atea向美国证券交易委员会提交的报告中 “风险因素” 标题下讨论的重要因素,包括10-K表年度报告、10-Q表季度报告、8-K表最新报告,这些因素可能会在向美国证券交易委员会提交的其他文件中不时更新,这些文件可在美国证券交易委员会查阅的网站是 www.sec.gov。这些和其他重要因素可能导致实际业绩与本新闻稿中前瞻性陈述所示的结果存在重大差异。任何此类前瞻性陈述均代表管理层截至本新闻稿发布之日的估计。尽管除非法律要求,否则Atea可能会选择在未来的某个时候更新此类前瞻性陈述,但它不承担任何更新此类前瞻性陈述的义务,即使随后发生的事件导致我们的观点发生变化。在本新闻稿发布之日之后的任何一天,不应将这些前瞻性陈述视为Atea的观点。

Contacts

联系人

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

乔纳·巴恩斯
投资者关系和企业传播高级副总裁
617-818-2985
Barnes.jonae@ateapharma.com

Will O'Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

威尔·奥康纳
斯特恩投资者关系
212-362-1200
will.oconnor@sternir.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发